Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia – 1/22/2024
/ PORTFOLIO NEWS
RiverVest is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.
2024
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 – 12/10/2024
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH – 12/10/2024
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors – 12/3/2024
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI – 12/19/2024
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD) – 11/15/2024
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma – 11/12/2024
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy- 11/12/2024
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates – 11/11/2024
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors – 11/7/2024
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results – 11/7/2024
OncoResponse Announces Phase 1 results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer- 11/7/2024
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors- 10/10/2024
InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance – 10/7/2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million – 10/4/2024
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia – 9/18/2024
Glycomine Receives FDA Fast Track Designation for BLM101 for the Treatment of PMM2-CDG- 9/18/2024
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis – 9/3/2024
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Noval Inhaled Nintedanib – 8/12/2024
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors- 8/8/2024
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors- 8/5/2024
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older – 7/25/2024
Integrated DNA Technologies Announces New Licensing Agreement with SeQure Dx to Advance CRISPR-based Therapeutics – 7/15/2024
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC – 7/8/2024
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies – 6/17/2024
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress – 6/14/2024
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress – 6/5/2024
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D – 5/29/2024
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
– 5/20/2024
Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
– 4/4/2024
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection- 3/25/2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies – 3/19/2024
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis – 3/14/2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG – 3/4/2024
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers – 1/23/2024
2023
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting – 12/11/2023
VentureMed Receives Transitional Pass-through Payment (TPT) for FLEX Vessel Prep™ System – 11/8/2023
Spruce Biosciences Completes Target Enrollment of Cahmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia – 10/18/2023
Reneo Pharmaceuticals Announces Last Patient Last visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) – 10/9/2023
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies – 9/27/2023
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics – 9/5/2023
Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refactory (R/R) Acute Myeloid Leukemia (AML) – 8/15/2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results 8/14/2023
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results 8/10/2023
Allakos provides Business Update and Reports Second Quarter 2023 Financial Results 8/9/2023
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update 8/3/2023
Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan 6/20/2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at European Hematology Association (EHA) 2023 Congress 6/9/2023
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment 6/1/2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 5/25/2023
OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy 5/18/2023
Reports First Quarter 2023 Financial Results and Provides Corporate Updates – 5/15/2023
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results 5/11/2023
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors – 5/10/2023
Provides Business Update and Reports First Quarter 2023 Financial Results – 5/9/2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results – 5/9/2023
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update – 5/4/2023
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock – 5/3/2023
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis– 4/11/2023
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors– 4/6/2023
Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023
Wugen, Inc. Announces CEO Transition — Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer – 3/21/2023
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023
Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 3/6/2023
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023
Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023
Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023
Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023
2022
Miurm Pharmaceuticals‘ LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022
Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D – 12/1/2022
SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients – 11/16/2022
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies – 11/15/2022
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) – 10/24/2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer – 10/17/2022
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older – 10/14/2022
Teleflex Completes Acquisition of Standard Bariatrics – 9/28/2022
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche – 9/7/2022
Teleflex to Expand It’s Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery – Signs Definitive Agreement to Acquire Standard Bariatrics – 8/22/2022
Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis. – 8/16/2022
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – 8/4/2022
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results – 8/4/2022
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates – 7/27/2022
Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/RT-ALL/LBL 7/19/2022
Allakos, Inc. Provides Business Update and Reports First Quarter 2022 Financial Results – 5/6/2022
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update – 3/23/2022
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/RT-ALL/LBL, 3/15/2022
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates – 3/14/2022
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update – 3/9/2022
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results – 3/1/2022
Standard Bariatrics Achieves Final Series B Funding Early, 2/28/2022
Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse – 2/15/2022
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma – 1/21/2022
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors – 1/20/2021
Titan SGS from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses – 1/19/2022
2021
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101 – 12/17/2021
InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA – 12/13/2021
Standard Bariatrics, Inc. Reaches Sales Milestone With Titan SGS™ – 12/13/2021
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma – 11/30/2021
Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection – 11/17/2021
Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment – 11/17/2021
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome – 11/15/2021
Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting – 11/12/2021
Scout Bio Named Best New Start-Up for 2021 – 11/08/2021
Biolinq raises $100 million for needle-free biosensors for diabetes monitoring – 11/2/2021
Xilio Therapeutics Announces Closing of Initial Public Offering – 10/26/2021
U.S. FDA Approves LIVMARLI (Maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older – 9/29/2021
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors – 9/16/2021
Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia – 9/9/2021
Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality – 8/17/2021
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates – 8/10/2021
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results – 8/9/2021
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update – 8/5/2021
SeQure Dx Announces $17.5M Series A Funding – 8/3/2021
Mirum Pharmaceuticals And GC Pharma Enter Into Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea – 7/26/2021
Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021
Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021
Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021
Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021
© Copyright RiverVest® All Rights Reserved.